** Shares of Incyte INCY.O rise 5.1% to $113.02

** The drugmaker says European Medicines Agency's key panel recommended approval of Opzelura, its skin cream for inflammatory conditions, for adults with moderate atopic dermatitis, a common type of eczema

** Says Opzelura could become the first steroid-free skin cream of its kind in the EU for patients with moderate eczema who did not respond well to standard creams

** Says late-stage data showed the cream improved eczema symptoms by Week 8, helped keep the condition under control through Week 24 and was well tolerated

** The European Commission will now review the recommendation; if approved, this would be Opzelura's second use in the EU after non-segmental vitiligo - INCY

** Including session's move, INCY up 14.1% YTD